Drug Integrated Polymer Fibers Market to exceed $88.8 mn by 2025

Drug Integrated Polymer Fibers Market size will exceed USD 88.8 million by 2025; according to a new research report by Global Market Insights Inc. 
 

Rising population, improved healthcare facilities in developing economies, growing implantable medical surgeries, technological advancement in medical textile engineering along with rise in R&D activities to replace traditional materials with innovative biomaterials will primarily drive the drug integrated polymer fibers market till 2025.
 

Drug integrated polymers fibers are generally made from biodegradable and biocompatible materials such as poly lactic acid and its derivatives such as PLLA, polydioxanone, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) and other copolymers. These fibers also called as pharmaceutical fibers and can be loaded with variety of drugs. These fibers are generally available in woven, knitted or braided form for a medical textile device. These fibers find wide applications in orthopaedics, drug delivery, vascular grafts and stents along with dermal healing. Although the market for drug integrated polymer fibers is very small at the moment, it is expected to rise significantly during the forecast period because of rise in innovative materials globally for orthopaedics, rise in old age population especially in European & North American continent.
 

Drug integrated polymer fibers are used to create implantable textile devices using a combination of resorbable as well as non-resorbable polymers. These devices can be made from different materials and are available in custom sizes and shapes to meet specific biological requirements. With rise in complexity along with technological innovations, textile devices are being designed to meet a broader range of applications than earlier which will boost the demand of drug integrated polymer fibers. Textiles are being considered as logical choice for soft tissue repair including hernias, ligaments and tendons due to its fibrous nature of human body.
 

Get more details on this report - Request Free Sample PDF
 

Drug integrated polymer fibers have been typically manufactured through melt extrusion at high shear and high temperatures- conditions that have severe limitations on pharmaceuticals and biologics. To address these concerns, a wet extrusion method has been developed for manufacturing drug loaded fibers, which occurs at lower temperature and has low shear stress. In wet extrusion process, a solution of polymers is put to pressure and is injected in a coagulating bath comprised of solution that is miscible with solvent which dissolves the solvent.
 

Browse key industry insights spread across 280 pages with 350 market data tables & 27 figures & charts from the report, “Drug Integrated Polymer Fibers Market Size, By Type (Polylactic acid, Polydioxanone, Polycaprolactone), By Applications (Drug Delivery, Orthopaedic Sutures, Vascular Stents, Vascular Grafts, Dermal Wound Healing) Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2018 – 2025” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/drug-integrated-polymer-fibers-market
 

Progress in topical fiber-based biologics and pharmaceuticals along with breakthrough in regenerative medicine and tissue engineering and is paving the next generation orthopedic medical products market. Controlled pharmaceutical delivery through biodegradable fibers has the potential to revolutionize many applications including orthopaedics.
 

Usage of traditional surgical methods in developing nations along with high cost of drug integrated polymer fibers are some of the factor that can restraint the market from its full growth.
 

Drug integrated polymer fibers are being widely used in variety of biomedical applications as it exhibits both biocompatibility and biodegradability properties both highly important for medical textile applications. Biodegradable polymers such as PLA, PLLA, PGA, PCL involves cost effective production and can be up scaled easily with less complicated machinery. Also, the mechanical properties along with the degradation kinetics of these polymers can be tailored to match the requirements of intended applications by controlling curing temperature, curing time. Because of the flexible and fibrous nature of these polymers its medical textile applications have mainly targeted soft tissue replacement and the engineering of soft tissues, such as cardiac muscle, blood, nerve, cartilage and retina.
 

At present, only TissueGen Inc, and Micro Engineering Solutions are the two main players in this business. However, a large number of companies are expected to enter this business due to unknown hidden potential of these fibers in drug delivery.
 

Drug Integrated Polymer Fibers market research report includes in-depth coverage of the industry, with estimates & forecast in terms of volume in tons and revenue in USD million from 2014 to 2025, for the following segments:

Drug integrated polymer fibers market by type

• Polylactic acid
• Polydioxanone
• Polycaprolactone
• Others (PGA, PLGA, PDLL)

Drug integrated polymer fibers market by application

• Drug delivery
• Orthopaedic sutures
• Vascular stents
• Vascular grafts
• Dermal wound healing

The above information is provided on a regional and country basis for the following:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Rest of Middle East & Africa